Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Director Sander A. Flaum sold 2,340 shares of Eagle Pharmaceuticals stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total value of $126,219.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Eagle Pharmaceuticals Inc (NASDAQ EGRX) traded down $0.34 during mid-day trading on Wednesday, hitting $55.68. The company had a trading volume of 188,676 shares, compared to its average volume of 255,590. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.99 and a quick ratio of 3.88. The company has a market capitalization of $867.20, a P/E ratio of 17.08 and a beta of 1.32. Eagle Pharmaceuticals Inc has a 12-month low of $45.05 and a 12-month high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.00 by ($0.16). Eagle Pharmaceuticals had a net margin of 21.94% and a return on equity of 34.16%. The company had revenue of $46.80 million during the quarter, compared to analysts’ expectations of $53.65 million. During the same quarter last year, the firm earned $3.52 EPS. Eagle Pharmaceuticals’s revenue for the quarter was down 42.3% on a year-over-year basis. analysts predict that Eagle Pharmaceuticals Inc will post 2.57 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Smith Asset Management Group LP purchased a new position in Eagle Pharmaceuticals in the fourth quarter valued at about $187,000. Municipal Employees Retirement System of Michigan grew its stake in Eagle Pharmaceuticals by 68.1% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,300 shares during the last quarter. Campbell Newman Asset Management Inc. purchased a new position in Eagle Pharmaceuticals in the fourth quarter valued at about $200,000. MetLife Investment Advisors LLC purchased a new position in Eagle Pharmaceuticals in the fourth quarter valued at about $218,000. Finally, Schroder Investment Management Group purchased a new position in Eagle Pharmaceuticals in the third quarter valued at about $219,000.
EGRX has been the subject of several research analyst reports. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, March 1st. Royal Bank of Canada set a $71.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Monday, February 26th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $79.00 price objective on shares of Eagle Pharmaceuticals in a report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Eagle Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $62.33.
COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://ledgergazette.com/2018/03/14/eagle-pharmaceuticals-inc-egrx-director-sells-126219-60-in-stock.html.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.